Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma

被引：0

作者：

Sangjoon Park

Yoon Jin Cha

Sang Hyun Suh

Ik Jae Lee

Kyu-Sung Lee

Chang-Ki Hong

Jun Won Kim

机构：

[1] Yonsei University College of Medicine,Department of Radiation Oncology, Gangnam Severance Hospital

[2] Yonsei University College of Medicine,Department of Pathology

[3] Yonsei University College of Medicine,Department of Radiology

[4] Yonsei University College of Medicine,Department of Neurosurgery, Gangnam Severance Hospital

来源：

Journal of Cancer Research and Clinical Oncology | 2019年 / 145卷

关键词：

Meningioma; WHO grade I/II; Skull base neoplasm; Adjuvant radiotherapy; Surgical extent; Risk factors;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1351 / 1360

页数：9

共 50 条

[21] Treatment of skull base chordomas and low grade chondrosarcomas with carbon ion radiotherapy: Preliminary results of a phase I/II study
Schulzz-Ertner, D
Debus, J
Jaekel, O
Haberer, T
Wenz, F
Thilmann, C
RADIOLOGY, 2000, 217 : 149 - 149
[22] Surgery and protontherapy in Grade I and II skull base chondrosarcoma: A comparative retrospective study
Simon, Francois
Feuvret, Loic
Bresson, Damien
Guichard, Jean-Pierre
El Zein, Sophie
Bernet, Anne-Laure
Labidi, Moujahed
Calugaru, Valentin
Froelich, Sebastien
Herman, Philippe
Verillaud, Benjamin
PLOS ONE, 2018, 13 (12):
[23] Prognostic Value of Ki-67 Labeling Index and Postoperative Radiotherapy in WHO Grade II Meningioma
Choi, Yunseon
Lim, Do Hoon
Yu, Jeong Il
Jo, Kyungil
Nam, Do-Hyun
Seol, Ho Jun
Lee, Jung-Il
Kong, Doo-Sik
Suh, Yeon-Lim
Nam, Heerim
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 18 - 23
[24] WHO grade II meningioma: Epidemiology, survival and contribution of postoperative radiotherapy in a multicenter cohort of 88 patients
Poulen, G.
Vignes, J-R
Le Corre, M.
Loiseau, H.
Bauchet, L.
NEUROCHIRURGIE, 2020, 66 (02) : 73 - 79
[25] Atypical Histological Features as a Risk Factors for Recurrence in Newly Diagnosed WHO Grade I Meningioma
Chiba, Keitaro
Sugawara, Takashi
Kobayashi, Daisuke
Sato, Akihito
Murota, Yasuhiro
Maehara, Taketoshi
NEUROLOGIA MEDICO-CHIRURGICA, 2021, 61 (11) : 647 - 651
[26] Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma
Dorota Lubgan
Sandra Rutzner
Ulrike Lambrecht
Karl Rössler
Michael Buchfelder
Ilker Eyüpoglu
Rainer Fietkau
Sabine Semrau
Journal of Neuro-Oncology, 2017, 134 : 407 - 416
[27] Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma
Jenkinson, Michael D.
Weber, Damien C.
Haylock, Brian J.
Sherratt, Frances C.
Young, Bridget
Weller, Michael
Bulbeck, Helen
Culeddu, Giovanna
Hughes, Dyfrig A.
Brain, Alice
Das, Kumar
Preusser, Matthias
Francis, Priya
Gamble, Carrol
JOURNAL OF NEUROSURGERY, 2018, 129 (04) : 1104 - 1105
[28] Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma
Lubgan, Dorota
Rutzner, Sandra
Lambrecht, Ulrike
Roessler, Karl
Buchfelder, Michael
Eyuepoglu, Ilker
Fietkau, Rainer
Semrau, Sabine
JOURNAL OF NEURO-ONCOLOGY, 2017, 134 (02) : 407 - 416
[29] Risk factors associated with higher WHO grade in meningiomas: a multicentric study of 552 skull base meningiomas
May, Michaela
Sedlak, Vojtech
Pecen, Ladislav
Priban, Vladimir
Buchvald, Pavel
Fiedler, Jiri
Vaverka, Miroslav
Lipina, Radim
Reguli, Stefan
Malik, Jozef
Cerny, Martin
Netuka, David
Benes, Vladimir
SCIENTIFIC REPORTS, 2025, 15 (01):
[30] Using texture analysis in brain MR imaging to differentiate between WHO Grade I and II Meningioma
Turki, Alharbi H.
Abdullah, Abujamea H.
Hussein, Alsakkaf M.
BIOSCIENCE RESEARCH, 2021, 18 (03): : 2229 - 2237

← 1 2 3 4 5 →